^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xatmep (methotrexate oral solution)

    Associations

    News

    Trials
    Company:
    Azurity Pharma
    Drug class:
    THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Jun 2026
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
    1year
    SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
    1year
    A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov)
    P1/2, N=15, Recruiting, University of Chicago | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Iclusig (ponatinib) • vincristine • Xatmep (methotrexate oral solution)
    1year
    A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov)
    P1/2, N=15, Active, not recruiting, University of Chicago | Not yet recruiting --> Active, not recruiting | N=33 --> 15 | Initiation date: Apr 2025 --> Sep 2024
    Enrollment closed • Enrollment change • Trial initiation date
    |
    Iclusig (ponatinib) • vincristine • Xatmep (methotrexate oral solution)
    over1year
    A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, University of Chicago | Initiation date: Apr 2024 --> Apr 2025
    Trial initiation date
    |
    Iclusig (ponatinib) • vincristine • Xatmep (methotrexate oral solution)
    over1year
    Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants (clinicaltrials.gov)
    P=N/A, N=39, Completed, The Hospital for Sick Children | Recruiting --> Completed | N=304 --> 39
    Trial completion • Enrollment change
    |
    methotrexate • Xatmep (methotrexate oral solution)
    almost2years
    A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, University of Chicago
    New P1/2 trial
    |
    Iclusig (ponatinib) • vincristine • Xatmep (methotrexate oral solution)
    2years
    SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Sep 2024
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
    3years
    SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2022
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
    4years
    SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Clinical • Enrollment closed
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • mercaptopurine • Xatmep (methotrexate oral solution)
    almost5years
    Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=58, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Clinical • Trial suspension
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine • Xatmep (methotrexate oral solution)
    almost5years
    Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=58, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jul 2021 --> Jun 2022
    Clinical • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    ABL2 fusion
    |
    dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine • Xatmep (methotrexate oral solution)